David Liberg

Immunology and Microbiology · Life Sciences

17h-index1.6kcitations67works3.22yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immune Cell Function and Interaction(15), Immunotherapy and Immune Responses(11), Cervical Cancer and HPV Research(10), Cancer Immunotherapy and Biomarkers(10), Virus-based gene therapy research(10)

Publications67 total

Myeloid-stromal IL1RAP as a therapeutic vulnerability in pancreatic cancer: Rationale for a neoadjuvant chemoimmunotherapy clinical trial.
Journal of Clinical Oncology·2026
Abstract B006: Exploiting Myeloid-Stromal IL1RAP as a Therapeutic Vulnerability to Improve Chemoimmunotherapy Sensitivity in Pancreatic Cancer
Cancer Research·2025
Abstract B091: Interleukin-1 Receptor Accessory Protein (IL1RAP) overexpression is associated with worse outcome in PDAC and can be reversed by nadunolimab treatment
Cancer Research·2025
Figure S6 from HPV16-Expressing Tumors Release Multiple IL1 Ligands to Orchestrate Systemic Immunosuppression Whose Disruption Enables Efficacy of a Therapeutic Vaccine
2025Open Access
Data from HPV16-Expressing Tumors Release Multiple IL1 Ligands to Orchestrate Systemic Immunosuppression Whose Disruption Enables Efficacy of a Therapeutic Vaccine
2025Open Access
Figure S7 from HPV16-Expressing Tumors Release Multiple IL1 Ligands to Orchestrate Systemic Immunosuppression Whose Disruption Enables Efficacy of a Therapeutic Vaccine
2025Open Access
Figure S5 from HPV16-Expressing Tumors Release Multiple IL1 Ligands to Orchestrate Systemic Immunosuppression Whose Disruption Enables Efficacy of a Therapeutic Vaccine
2025Open Access
Table S2 from HPV16-Expressing Tumors Release Multiple IL1 Ligands to Orchestrate Systemic Immunosuppression Whose Disruption Enables Efficacy of a Therapeutic Vaccine
2025Open Access
Table S1 from HPV16-Expressing Tumors Release Multiple IL1 Ligands to Orchestrate Systemic Immunosuppression Whose Disruption Enables Efficacy of a Therapeutic Vaccine
2025Open Access
Figure S1 from HPV16-Expressing Tumors Release Multiple IL1 Ligands to Orchestrate Systemic Immunosuppression Whose Disruption Enables Efficacy of a Therapeutic Vaccine
2025Open Access
Figure S3 from HPV16-Expressing Tumors Release Multiple IL1 Ligands to Orchestrate Systemic Immunosuppression Whose Disruption Enables Efficacy of a Therapeutic Vaccine
2025Open Access
Figure S2 from HPV16-Expressing Tumors Release Multiple IL1 Ligands to Orchestrate Systemic Immunosuppression Whose Disruption Enables Efficacy of a Therapeutic Vaccine
2025Open Access
Figure S4 from HPV16-Expressing Tumors Release Multiple IL1 Ligands to Orchestrate Systemic Immunosuppression Whose Disruption Enables Efficacy of a Therapeutic Vaccine
2025Open Access
IL1RAP Expression in Human Atherosclerosis: A Target of Novel Antibodies to Reduce Vascular Inflammation and Adhesion
Journal of the American Heart Association·2025· 3 citedOpen Access
HPV16-Expressing Tumors Release Multiple IL1 Ligands to Orchestrate Systemic Immunosuppression Whose Disruption Enables Efficacy of a Therapeutic Vaccine
Cancer Discovery·2025· 2 citedOpen Access
Abstract 309: Adding nadunolimab to chemotherapy or antibody drug-conjugates (ADCs) may improve antitumor efficacy and counteract peripheral neuropathy
Cancer Research·2025
Abstract 2875: IL1RAP-targeting antibody-drug conjugate: a novel therapeutic targeting both tumor cells and the tumor microenvironment
Cancer Research·2025
Blocking IL1RAP on cancer-associated fibroblasts in pancreatic ductal adenocarcinoma suppresses IL-1-induced neutrophil recruitment
Journal for ImmunoTherapy of Cancer·2024· 12 citedOpen Access
IL1RAP Blockade With a Monoclonal Antibody Reduces Cardiac Inflammation and Preserves Heart Function in Viral and Autoimmune Myocarditis
Circulation Heart Failure·2024· 8 citedOpen Access
1303 Antibody drug conjugate (ADC) payload-induced IL1 suggests potential for anti-IL1RAP therapy combination for enhanced treatment efficacy and prevention of neuropathy
Regular and Young Investigator Award Abstracts·2024Open Access
page 1 of 4Next →

Frequent Co-authors

Tomas Leanderson(18), Elin Jaensson Gyllenbäck(9), Caitríona Grönberg(8), Camilla Rydberg Millrud(8), Anders Olsson(7), Mikael Sigvardsson(7), Fredrik Ivars(6), Sara Rattik(6), Martin Stenström(5), Eva Källberg(5), Marie Törngren(5), Petter Skoog(5), G. Forsberg(5), Per Björk(4), Gabriel Svensson Birkedal(4), Karin von Wachenfeldt(4), Annika Sanfridson(4), Morgane Lecointre(4), Jérémy Guillot(4), Rachel Marcone(4)